A sensitive electrochemical detection of metronidazole in synthetic serum and urine samples using low-cost screen-printed electrodes modified with reduced graphene oxide and C60

Monitoring the concentration of antibiotics in body fluids is essential to optimizing the therapy and minimizing the risk of bacteria resistance, which can be made with electrochemical sensors tailored with appropriate materials. In this paper, we report on sensors made with screen-printed electrode...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical analysis 2021-10, Vol.11 (5), p.646-652
Main Authors: Materón, Elsa Maria, Wong, Ademar, Freitas, Tayane Aguiar, Faria, Ronaldo Censi, Oliveira, Osvaldo N
Format: Article
Language:English
Subjects:
Antibiotics
Body fluids
Carbon
Drugs
Electrodes
Enzymes
Fullerenes
Graphene
High-performance liquid chromatography
Immunoassay
Metronidazole
Nanomaterials
Nanoparticles
Sensors
Urine
Voltammetry
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Monitoring the concentration of antibiotics in body fluids is essential to optimizing the therapy and minimizing the risk of bacteria resistance, which can be made with electrochemical sensors tailored with appropriate materials. In this paper, we report on sensors made with screen-printed electrodes (SPE) coated with fullerene (C60), reduced graphene oxide (rGO) and Nafion (NF) (C60-rGO-NF/SPE) to determine the antibiotic metronidazole (MTZ). Under optimized conditions, the C60-rGO-NF/SPE sensor exhibited a linear response in square wave voltammetry for MTZ concentrations from 2.5 x 10~7 to 34 x 10~6 mol/L, with a detection limit of 2.1 x 10~7 mol/L. This sensor was also capable of detecting MTZ in serum and urine, with recovery between 94% and 100%, which are similar to those of the standard chromatographic method (HPLC-UV). Because the C60-rGO-NF/SPE sensor is amenable to mass production and allows for MTZ determination with simple principles of detection, it fulfills the requirements of therapeutic drug monitoring programs.
ISSN:2095-1779
2214-0883
DOI:10.1016/jjpha.2021.03.004